Cargando…
Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745691/ https://www.ncbi.nlm.nih.gov/pubmed/33335030 http://dx.doi.org/10.1136/jitc-2020-001675 |
_version_ | 1783624655435726848 |
---|---|
author | Rosner, Samuel Agrawal, Yuri Sun, Daniel Q Aygun, Nafi Schollenberger, Megan D Lipson, Evan Naidoo, Jarushka |
author_facet | Rosner, Samuel Agrawal, Yuri Sun, Daniel Q Aygun, Nafi Schollenberger, Megan D Lipson, Evan Naidoo, Jarushka |
author_sort | Rosner, Samuel |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treated patients who developed immune-mediated ototoxicity, identified by a multidisciplinary immune-related toxicity team. This is the largest case series to date and identifies bilateral high-frequency hearing loss and tinnitus as the most common reported symptoms and can be associated with abnormal speech reception thresholds and word recognition ability on audiogram in select patients. We propose multidisciplinary evaluation of patients with suspected otologic irAEs including referral to otolaryngology, audiometry evaluation±magnetic resonance imaging for evaluation of suspected immune-mediated ototoxicity. |
format | Online Article Text |
id | pubmed-7745691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-77456912020-12-28 Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma Rosner, Samuel Agrawal, Yuri Sun, Daniel Q Aygun, Nafi Schollenberger, Megan D Lipson, Evan Naidoo, Jarushka J Immunother Cancer Case Report Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treated patients who developed immune-mediated ototoxicity, identified by a multidisciplinary immune-related toxicity team. This is the largest case series to date and identifies bilateral high-frequency hearing loss and tinnitus as the most common reported symptoms and can be associated with abnormal speech reception thresholds and word recognition ability on audiogram in select patients. We propose multidisciplinary evaluation of patients with suspected otologic irAEs including referral to otolaryngology, audiometry evaluation±magnetic resonance imaging for evaluation of suspected immune-mediated ototoxicity. BMJ Publishing Group 2020-12-16 /pmc/articles/PMC7745691/ /pubmed/33335030 http://dx.doi.org/10.1136/jitc-2020-001675 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Case Report Rosner, Samuel Agrawal, Yuri Sun, Daniel Q Aygun, Nafi Schollenberger, Megan D Lipson, Evan Naidoo, Jarushka Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma |
title | Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma |
title_full | Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma |
title_fullStr | Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma |
title_full_unstemmed | Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma |
title_short | Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma |
title_sort | immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745691/ https://www.ncbi.nlm.nih.gov/pubmed/33335030 http://dx.doi.org/10.1136/jitc-2020-001675 |
work_keys_str_mv | AT rosnersamuel immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma AT agrawalyuri immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma AT sundanielq immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma AT aygunnafi immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma AT schollenbergermegand immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma AT lipsonevan immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma AT naidoojarushka immunemediatedototoxicityassociatedwithimmunecheckpointinhibitorsinpatientswithmelanoma |